Pre-made Sotrovimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-530
Pre-Made Sotrovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sotrovimab is an investigational monoclonal antibody therapy medication with activity against SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Sotrovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody|
|Target||SARS-CoV-2 Spike RBD|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||7jx3:AB/6ws6:EF/6wps:CD:FG:HL/6wpt:DE:HL|
|95-98% SI Structure||None|